Is Clinical Risk Score a Useful Predictive Marker of Early Recurrence Among Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors?
Bala Basak Oven1, Ilker Nihat Okten2, Ahmet Bilici3, Ayse Irem Yasin4, Sinan Koca5, Ezgi Yuzugullu1, Serkan Celik1, Yasin Kutlu2, Mesut Seker4, Eda Tanrikulu Simsek6, Mahmut Gumus51Department of Medical Oncology, Yeditepe University Faculty of Medicine, Istanbul, Türkiye, 2Department of Medical Oncology, Istanbul Onko Oncology Hospital, istanbul, Türkiye, 3Department of Medical Oncology, Medipol University, Istanbul, Türkiye, 4Department of Medical Oncology, Bezmi Alem Vakıf Gureba University, Istanbul, Türkiye, 5Department of Medical Oncology, Medeniyet University, Istanbul, Türkiye, 6Department of Medical Oncology, Anadolu Health Center, Istanbul, Türkiye
Objectives: The addition of CDK4/6 inhibitors to standard hormonotherapy improved progression-free survival(PFS) of hormone-positive, HER-2 negative metastatic breast cancer(mBC). We analyzed clinicopathological risk factors predict ing early recurrence in mBC patients treated with a combination of CDK4/6 inhibitor and hormonotherapy. Methods: 229 patients were included, and 95 recurrences were seen. Median ER and PR expressions, ki67 levels, meta static sites, number of metastasis, and grade were related to recurrence. Patients were classified according to the pres ence of prognostic factors: group 1 included patients with 0-1 risk factors, group 2 with 2-3 risk factors, and group 3 with ?4risk factors. Results: Median ER, PR, and ki67 levels were 90, 60, and 25,respectively. Median ER, PR, Kİ67, grade, metastatic site, and the number of metastasis were related to PFS. Advanced CDK4/6 line and response were significant for PFS.Median PFS was 6.5 months for recurrent patients. According to the predictive model, patients who recurred before 6.5 months had a high-risk group (group 2,3). PS, family history, CDK4/6 inhibitor types were found to be related to PFS among the recurrent group. Conclusion: There is a need for a prospective design study to determine the clinicopathological markers identifying early recurrence under CDK4/6 inhibitors so new combination therapies or alternatives can be developed. Keywords: Breast cancer, CDK4/6 inhibitors, clinical risk factors
Cite This Article
Oven B, Okten I, Bilici A, Yasin A, Koca S, Yuzugullu E, Celik S, Kutlu Y, Seker M, Simsek E, Gumus M. Is Clinical Risk Score a Useful Predictive Marker of Early Recurrence Among Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors?. EJMI. 2024; 8(2): 106-112
Corresponding Author: Bala Basak Oven